ESOC 2025 | The potential of blood-based biomarkers to stratify patient risk of developing hemorrhagic stroke
Maria Alonso De Leciñana, MD, PhD, La Paz University Hospital, Madrid, Spain, discusses the potential of blood-based biomarkers to stratify patient risk of developing hemorrhagic stroke, particularly in the context of cerebral microbleeds and small vessel disease. Dr Leciñana highlights biomarkers that can be used to predict stroke risk and prognosis. However, she notes that these biomarkers are not yet widely implemented in clinical practice and require further validation in clinical trials. This interview took place at the 11th European Stroke Organisation Conference (ESOC) in Helsinki, Finland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
They may guide. I mean, there are certain biomarkers that can stratify patient risk of developing bleeding. For example, in patients with atrial fibrillation, it has been described that high levels of metalloproteinase 2 and high levels of tissue inhibitors of metalloproteinases can predict cerebral microbleeds and the small vessel disease, which are signs of risk of developing parenchymal hemorrhage...
They may guide. I mean, there are certain biomarkers that can stratify patient risk of developing bleeding. For example, in patients with atrial fibrillation, it has been described that high levels of metalloproteinase 2 and high levels of tissue inhibitors of metalloproteinases can predict cerebral microbleeds and the small vessel disease, which are signs of risk of developing parenchymal hemorrhage. So this may help. And there are also some other biomarkers, not only proteins, but also certain microRNAs that can be associated with a higher risk of hemorrhagic stroke. But still, these are not really implemented in clinical practice yet. They are promising, but they are not really implemented. We can also find some biomarkers of prognosis after intracerebral hemorrhage. But they can mark patients at higher risk of mortality or of poor evolution. This may help to take clinical decisions, but again, they must be proven in clinical trials.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
